ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ARCTURUS THERAPEUTICS HOLDINGS INC

Financial Performance:

• No specific revenue, profit margin, cash flow, or debt figures were disclosed in the transcript.
• Potential for a $40 million milestone payment from Thermo Fisher triggered upon a successful Phase 2 to Phase 3 decision for the Cystic Fibrosis (CF) program, which would split the potential deal contribution in half.
• Thermo Fisher has initiated pre-trial preparation (at-risk steps) to support rapid Phase 3 initiation pending the go/no-go decision.

Guidance and Future Outlook:

• 2027 Catalysts: Company has established 2027 as a pivotal year with two major data presentations: Q2 2027 for complete Phase 2 data of the CF program and H2 2027 for top-line data of the reformulated OTC program (ARCT 2601).
• OTC Program: Clinical trials for the reformulated ARCT 2601 (Lunar 2.0) are anticipated to start in early 2026.
• PKU Entry: Planning to submit an Investigational New Drug (IND) application for Phenylketonuria (PKU) in the second half of 2026, enabled by Lunar 2.0 technology.
• CF Program: Full data presentation scheduled for Q2 2027; top-line data expected sometime between now and that presentation to facilitate the Phase 3 decision.

Business Segments and Product Lines:

• Lunar Platform (mRNA Delivery): Lunar 2.0 lipid nanoparticle technology demonstrated 38x higher potency in primates compared to Lunar 1.0, enabling lower doses, less frequent administration (shifting from bi-weekly to potentially monthly), and reduced administration time (3 hours to <1 hour).
• Cystic Fibrosis (ARCT 101): Inhaled mRNA therapeutic for Class 1 CF (patients with no CFTR protein, ~15% of the market, up to 40% in specific regions).
  • Current Status: Enrolling up to 20 patients in a 12-week, 10mg dose study (Cohort 4) across the US, Turkey, and Israel.
  • Study Design: Enrolled patients have baseline lung function between 45% and 85% predicted FEV1 (lowered ceiling and raised floor to improve signal detection); utilizes stricter baseline reproducibility protocols.
• Ornithine Transcarbamylase (OTC) Deficiency: Intravenously dosed mRNA therapeutic (ARCT 2601, reformulated from ARCT 810).
  • Efficacy: Already proven to normalize both ammonia and glutamine levels in stable adults.
  • Strategic Pivot: Transitioning from a "dark horse" to a featured program due to convenience improvements and high likelihood of success; targeting a multi-billion dollar peak sales opportunity.
• PKU (Phenylketonuria): New pipeline addition enabled by Lunar 2.0's ability to deliver high-dose mRNA to the liver, a target previously considered intractable due to dosing frequency constraints.

Market and Competitive Landscape:

• CF Market: Differentiates from modulators (which fix broken transporters) by building a new transporter via mRNA; addresses Class 1 patients who are "nulls" and have no current therapeutic options.
• OTC Market: Differentiates from current standard-of-care ammonia scavengers by also controlling glutamine levels, which cross the blood-brain barrier and cause neurological issues; current market lacks a disease-modifying cure.
• PKU Market: Potential to enter a space with existing high-valuation companies but previously limited by technical barriers to mRNA delivery efficiency.
• Lunar 2.0 Advantage: The 38x potency improvement is described as unprecedented in the field, offering a clear differentiation from competitors and existing Lunar 1.0-based products.

Risks and Challenges:

• Clinical Signal Detection: Previous CF cohorts faced challenges with variable baseline spirometry; the new cohort design mitigates this but success is not guaranteed.
• Regulatory Path: A small cohort (approx. 6 patients) of Lunar 2.0 data is required to validate the new formulation with the FDA before defining the pivotal trial path for adults or pediatrics.
• Disease Heterogeneity: OTC deficiency presents differently in stable adult females vs. dying male children; distinct pivotal trial paths will be required.
• Enrollment: Dependence on recruiting patients from specific regions (Turkey, Israel) with higher prevalence of Class 1 CF to ensure statistical power.

Management Commentary and Tone:

• Confidence: Management expressed high confidence, particularly regarding the OTC program, which is no longer viewed as speculative but as a "featured program" with high success likelihood.
• Narrative: CEO Joe Payne compared the Lunar 2.0 breakthrough to Alnylam's 2012 lipid formulation shift, predicting significant enterprise value creation.
• Urgency: Strong motivation to reach the Phase 3 decision for CF quickly to unlock Thermo Fisher funding, though management retains flexibility on exact top-line data release timing.
• Tone: Optimistic and strategic, emphasizing that 2027 will be the culmination of 12 years of R&D.

Analyst Questions and Answers:

• CF Enrollment: Confirmed enrollment is active and expected to complete by year-end; specific top-line data date is not set but will be shared concurrently with the Phase 3 go/no-go decision.
• CF Data Readouts: Expectations are for stability at lower lung function (45%) and demonstrable improvement at higher function (85%); regulatory and community feedback indicates high receptiveness to even modest benefits given the lack of alternatives for Class 1 CF.
• OTC Validation: Explained that OTC protein levels can be measured in plasma due to the liver's sloughing nature, providing a direct metric to compare Lunar 1.0 vs. 2.0; FDA has reviewed primate data and is receptive to the new formulation.
• Phase 3 Planning: Phase 3 for CF will leverage REACH study data for powering and statistical analysis; Thermo Fisher is prepping for rapid execution upon success.
• Lunar 2.0 Scope: Beyond OTC, the technology unlocks new liver targets like PKU, which were previously unviable due to dosing frequency requirements.

Other Key Points:

• Safety: Lunar 1.0 technology has an established safety profile with an approved COVID vaccine used in 30+ countries; Lunar 2.0 builds on this foundation.
• Clinical Endpoints: CF study includes High-Resolution CT scans, Lung Clearance Index (LCI), quality of life measures, and spirometry to provide a holistic view of efficacy.
• Strategic Focus: The company is pivoting OTC treatment towards home administration to reduce clinical burden, aiming to establish a new standard of care.